Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers

Neural Regeneration Research

Volumn 8, Issue 33, 2013, Pages 3107-3115

  Yuan, Zuan Ning ^a,b   Du, Min Ge ^a,b   Chen, Yi Wen ^c   Dou, Fei ^a,b  

^a Beijing Normal University   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Alpha synuclein; Alzheimer's disease; Amyloid beta; Antibody library construction; Grants supported paper; Humanized antibody; Immunotherapy; Neural regeneration; Neuroregeneration; Oligomer; Parkinson's disease; Phage display; Single domain antibody

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN [1-42]; IMMUNOGLOBULIN F (AB) FRAGMENT; UNCLASSIFIED DRUG;

ADULT; ANTIBODY LIBRARY; ANTIBODY SCREENING; ARTICLE; BIOPANNING; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; OLIGOMERIZATION; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84889873963     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.33.004     Document Type: Article

References (29)

1. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-12.
2. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24(4):219-224.
3. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416(6880):535-539.
4. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100(18):10417-10422.
5. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79-84.
6. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082):352-357.
7. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8): 837-842.
8. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177.
9. Solomon B, Frenkel D. Immunotherapy for Alzheimer's disease. Neuropharmacology. 2010;59(4-5):303-309.
10. Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nat Med. 2002;8(3):199-200.
11. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3(10):824-828.
12. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38(4):547-554.
13. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46-54.
14. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006;6(5):404-416.
15. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet. 1994;7(1):13-21.
16. Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibo dies for therapeutics. Curr Opin Biotechnol. 2002;13(6): 593-597.
17. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005; 23(9):1126-1136.
18. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486-489.
19. Kayed R, Head E, Sarsoza F, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.
20. Zameer A, Kasturirangan S, Emadi S, et al. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol. 2008;384(4):917-928.
21. Wang XP, Zhang JH, Wang YJ, et al. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett. 2009;583(3):579-584.
22. Lafaye P, Achour I, England P, et al. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol Immunol. 2009;46(4):695-704.
23. Habicht G, Haupt C, Friedrich RP, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A. 2007;104(49):19232-19237.
24. Medecigo M, Manoutcharian K, Vasilevko V, et al. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. J Neuroimmunol. 223;(1-2):104-114.
25. Hendershot L, Bole D, Kohler G, et al. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol. 1987;104(3): 761-767.
26. Prelli F, Frangione B. Franklin's disease: Ig gamma 2 H chain mutant BUR. J Immunol. 1992;148(3):949-952.
27. Britschgi M, Olin CE, Johns HT, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(29): 12145-12150.
28. Hilschmann N, Craig LC. Amino acid sequence studies with Bence-Jones proteins. Proc Natl Acad Sci U S A. 1965;53(6):1403-1409.
29. Ward ES, Gussow D, Griffiths AD, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341(6242): 544-546.